Radiomics/Radiogenomics in Lung Cancer: Basic Principles and Initial Clinical Results.
Athanasios K AnagnostopoulosAnastasios GaitanisIoannis GkiozosEmmanouil I AthanasiadisSofia N ChatziioannouKonstantinos N SyrigosDimitris ThanosAchilles N ChatziioannouNickolas PapanikolaouPublished in: Cancers (2022)
Lung cancer is the leading cause of cancer-related deaths worldwide, and elucidation of its complicated pathobiology has been traditionally targeted by studies incorporating genomic as well other high-throughput approaches. Recently, a collection of methods used for cancer imaging, supplemented by quantitative aspects leading towards imaging biomarker assessment termed "radiomics", has introduced a novel dimension in cancer research. Integration of genomics and radiomics approaches, where identifying the biological basis of imaging phenotypes is feasible due to the establishment of associations between molecular features at the genomic-transcriptomic-proteomic level and radiological features, has recently emerged termed radiogenomics. This review article aims to briefly describe the main aspects of radiogenomics, while discussing its basic limitations related to lung cancer clinical applications for clinicians, researchers and patients.
Keyphrases
- high resolution
- papillary thyroid
- lymph node metastasis
- high throughput
- end stage renal disease
- single cell
- ejection fraction
- squamous cell
- newly diagnosed
- chronic kidney disease
- contrast enhanced
- squamous cell carcinoma
- gene expression
- magnetic resonance imaging
- prognostic factors
- mass spectrometry
- rna seq
- fluorescence imaging
- magnetic resonance
- childhood cancer
- patient reported